The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy

Camrelizumab synergizes with apatinib or transarterial chemoembolization via tumor immunity and chemosensitivity. This study aimed to investigate the efficacy and safety of camrelizumab plus apatinib with or without drug-eluting bead transarterial chemoembolization (DEB-TACE) in unresectable hepatoc...

Full description

Saved in:
Bibliographic Details
Published in:Clinics and research in hepatology and gastroenterology 2023-01, Vol.47 (1), p.102060-102060, Article 102060
Main Authors: Wang, Manzhou, Sun, Limin, Han, Xinwei, Ren, Jianzhuang, Li, Hao, Wang, Wenhui, Xu, Wenze, Liang, Chao, Duan, Xuhua
Format: Article
Language:English
Subjects:
Apatinib
camrelizumab
Carcinoma, Hepatocellular - drug therapy
Carcinoma, Hepatocellular - pathology
Chemoembolization, Therapeutic
Drug-eluting bead transarterial chemoembolization
Humans
Liver Neoplasms - pathology
Retrospective Studies
Second-line treatment
Treatment Outcome
Unresectable hepatocellular carcinoma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Camrelizumab synergizes with apatinib or transarterial chemoembolization via tumor immunity and chemosensitivity. This study aimed to investigate the efficacy and safety of camrelizumab plus apatinib with or without drug-eluting bead transarterial chemoembolization (DEB-TACE) in unresectable hepatocellular carcinoma (HCC) patients after progression to DEB-TACE plus apatinib. Eighty-nine unresectable HCC patients accepted previous DEB-TACE plus apatinib therapy, then further received second-line camrelizumab plus apatinib with or without DEB-TACE treatment. Treatment responses were calculated at 3 months (M3) and 6 months (M6). Survival and treatment-related adverse events were documented. Objective response rate and disease control rate were 39.3% and 80.9% at M3; meanwhile, they were 22.4% and 54.1% at M6. Furthermore, the median progression-free survival (PFS) (95% confidence interval (CI)) was 7.0 (6.2-7.8) months with a 1-year PFS rate of 18.4%; the median overall survival (OS) (95% CI) was 17.0 (15.3-18.7) months with a 1-year OS rate of 73.9%. Multivariable Cox's proportional hazards regression analysis presented that 3-4 times (vs. 0 time) of DEB-TACE, apatinib dose duration> 4 months, and camrelizumab dose duration> 5 months independently predicted longer PFS (all P 4 months independently predicted prolonged OS (all P
ISSN:2210-7401
2210-741X
DOI:10.1016/j.clinre.2022.102060